Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript

Impact · against what's priced in

Enliven Therapeutics is reporting updated Phase 1 data for ELVN-001 in chronic myeloid leukemia. While positive clinical updates are typically catalysts for small-cap biotech, the impact depends on whether these results exceed existing efficacy expectations for the lead candidate.

ELVN+0.60: No priced-in read yet

Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript

What matters in this story

How each ticker is affected

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript

What matters in this story

How each ticker is affected

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

Track these names every morning.

Where Will Neurocrine Biosciences Be in 5 Years?

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors

Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The Opportunity

Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript

What matters in this story

How each ticker is affected

Next reads from the same story arc

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript

What matters in this story

How each ticker is affected

Next reads from the same story arc

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

Track these names every morning.

Where Will Neurocrine Biosciences Be in 5 Years?

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors

Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The Opportunity